Savelli Giordano, Muni Alfredo, Barbieri Roberto, Valmadre Giuseppe, Biasiotto Giorgio, Minari Chiara, Ghimenton Claudio, Pagani Renato, Pecini Elisa, Falcone Matteo
Nuclear Medicine Unit, "Carlo Poma" Civic Hospital, Strada Lago Paiolo, 10 - 46100 Mantua, Italy.
Nuclear Medicine Unit, SS. Antonio e Biagio e Cesare Arrigo Hospital, 46100 Alessandria, Italy.
World J Oncol. 2014 Apr;5(2):72-76. doi: 10.14740/wjon739w. Epub 2014 May 6.
Prostate cancer is the second most commonly diagnosed neoplasm in men. This neoplasm has usually excellent prognosis, mostly consequent to the early diagnosis and the effective hormonal therapy. However, significant percentages of patients treated with total androgen blockade therapy, escape to treatment and evolve toward a more aggressive type of cancer. This clinical entity, named castration-resistant prostate cancer, has few and less effective therapeutic opportunities. Therefore, any additional information concerning possible biological targets to therapy is welcome. Here we describe two cases in which Ga-DOTANOC PET/CT evidenced the somatostatin receptor overexpression by prostate metastases. The presence of these receptors may support with a more strong evidence the possibility to administer somatostatin analogs as an adjuvant therapy.
前列腺癌是男性中第二常见的被诊断出的肿瘤。这种肿瘤通常预后良好，这主要归功于早期诊断和有效的激素治疗。然而，接受全雄激素阻断治疗的患者中有相当比例的人对治疗产生耐药，病情发展为更具侵袭性的癌症类型。这种临床实体被称为去势抵抗性前列腺癌，其治疗机会很少且效果不佳。因此，任何有关可能的治疗生物学靶点的额外信息都是受欢迎的。在此，我们描述两例病例，其中镓-多他胺PET/CT显示前列腺转移灶中生长抑素受体过度表达。这些受体的存在可能更有力地支持使用生长抑素类似物作为辅助治疗的可能性。
